• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

    43.04 -0.84 (-1.91%)
    Streaming Delayed Price Updated: 11:26 AM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 98,254
    Open 43.79
    Bid (Size) 42.90 (100)
    Ask (Size) 43.05 (200)
    Prev. Close 43.88
    Today's Range 42.03 - 44.26
    52wk Range 10.91 - 45.76
    Shares Outstanding 101,192,921
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Spyre Therapeutics to Participate in Upcoming March Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
    Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
    Via The Motley Fool

    Performance

    YTD
    +40.7%
    +40.7%
    1 Month
    +33.3%
    +33.3%
    3 Month
    +44.7%
    +44.7%
    6 Month
    +151.1%
    +151.1%
    1 Year
    +108.4%
    +108.4%

    More News

    Read More
    News headline image
    Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    Spyre Therapeutics' CEO Sells 15,000 Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Participate in Upcoming November Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗
    Via Benzinga
    News headline image
    Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
    Via Benzinga
    News headline image
    Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre (SYRE) Q2 R&D Up 23% Loss Narrows ↗
    Via The Motley Fool
    News headline image
    This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
    Via Benzinga
    News headline image
    SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
    Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
    The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
    What is the current price of Spyre Therapeutics, Inc. - Common Stock?
    The current price of Spyre Therapeutics, Inc. - Common Stock is 43.04
    When was Spyre Therapeutics, Inc. - Common Stock last traded?
    The last trade of Spyre Therapeutics, Inc. - Common Stock was at 02/26/26 11:26 AM ET
    What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
    The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 4.36B
    How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
    Spyre Therapeutics, Inc. - Common Stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.